Notice for alectinib (Roche Products Pty Limited)
Active ingredients
alectinib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Registration date